<DOC>
	<DOCNO>NCT00214318</DOCNO>
	<brief_summary>We hypothesize b2 adrenergic polymorphism affect b-receptor selectivity patient heart failure treat either b1-selective b-nonselective agent . b-2 polymorphism may contribute differ response drug treatment beta-blockers heart failure . Characterizing polymorphism may help explain variability degree `` selectivity '' action b-blockers b receptor , namely action specific b-1 b-2 receptor . Part A conducted University Utah , subject complete study related activity . Part B ( sub-study ) consist genotyping blood sample collect part A , complete University Wisconsin . Sub-study ( sample DNA isolation ) Part B entail analyze extra 10 mL blood take DNA isolation . Genotyping ( i.e . determination genetic makeup ) beta adrenergic polymorphism utilized polymerase chain reaction follow pyrosequencing .</brief_summary>
	<brief_title>Beta-2 Polymorphisms Beta Receptor Selectivity</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>systolic dysfunction ejection fraction â‰¤40 % symptomatic heart failure class 23 &gt; 18 year age optimal medical therapy HF exclude use betablockers within previous 30 day study active myocarditis hemodynamically significant valvular heart disease hypertrophic cardiomyopathy contraindication betablockers concomitant use betaagonists betaantagonist antiarrhythmic unstable angina myocardial infarction bypass surgery within 3 month significant renal insufficiency [ creatinine &gt; 2.5 mg/dL ] , liver disease , anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>